Primary Site >> Biliary tract Cancer
Gene >> EPHB2
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. PMID: 12692057 |
Ref: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. PMID: 16525641 Ref: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. PMID: 16767220 Ref: Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. PMID: 16950403 |
Ref: Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. PMID: 17551669 Ref: Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. PMID: 17708250 |
Ref: Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. PMID: 19445727 |
Ref: The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells. PMID: 20101459 Ref: Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. PMID: 20388063 |
Ref: Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. PMID: 21076843 |
Ref: Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. PMID: 22044563 Ref: L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. PMID: 22088438 Ref: Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. PMID: 22727731 |
Ref: Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. PMID: 23254774 Ref: PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. PMID: 23483557 Ref: Protective Effects of Guava Pulp on Cholestatic Liver Injury. PMID: 27335829 |
Ref: Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study. PMID: 24247752 Ref: Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine. PMID: 24551272 Ref: Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. PMID: 24788596 Ref: Increased EphB2 expression predicts cholangiocarcinoma metastasis. PMID: 25012246 Ref: Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. PMID: 25152244 Ref: Fibroblast Growth Factor 19 Activates the Unfolded Protein Response and Mitogen-Activated Protein Kinase Phosphorylation in H-69 Cholangiocyte Cells. PMID: 29093991 |
Ref: Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. PMID: 25663464 Ref: Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. PMID: 26090720 Ref: Pachymic acid inhibits tumorigenesis in gallbladder carcinoma cells. PMID: 26770369 |
Ref: Simvastatin Induces Apoptosis and Suppresses Insulin-Like Growth Factor 1 Receptor in Bile Duct Cancer Cells. PMID: 26470769 Ref: A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. PMID: 26614007 Ref: Downregulation of lncRNA-MALAT1 Affects Proliferation and the Expression of Stemness Markers in Glioma Stem Cell Line SHG139S. PMID: 26649728 Ref: Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. PMID: 26683364 Ref: Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. PMID: 26877611 Ref: Comparative study of antitumor effects of bromelain and papain in human cholangiocarcinoma cell lines. PMID: 26935541 Ref: miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma. PMID: 26968949 Ref: Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer. PMID: 27084680 Ref: Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation. PMID: 27627808 Ref: Long non-coding RNA CRNDE promotes gallbladder carcinoma carcinogenesis and as a scaffold of DMBT1 and C-IAP1 complexes to activating PI3K-AKT pathway. PMID: 27637083 |
Ref: The emerging role of long non-coding RNA in gallbladder cancer pathogenesis. PMID: 27894946 Ref: Growth Inhibition of Refractory Human Gallbladder Cancer Cells by Retinol, and Its Mechanism of Action. PMID: 28100868 Ref: Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. PMID: 28223426 Ref: The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer. PMID: 28285962 Ref: Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. PMID: 28412732 Ref: Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway. PMID: 28913568 |
Ref: Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway. PMID: 29110119 Ref: Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. PMID: 29348467 Ref: Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation. PMID: 29574153 Ref: EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. PMID: 29778567 Ref: Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling. PMID: 30160357 Ref: IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. PMID: 30278918 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 Ref: MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner. PMID: 30322054 |